Novel Pharmacotherapies in Diabetic Retinopathy

Overview

Journal Middle East Afr J Ophthalmol

Specialty Ophthalmology

Date 2015 May 8

PMID 25949073

Citations 10

Authors

Vaidehi S Dedania

Sophie J Bakri

Affiliations

Soon will be listed here.

Abstract

This is a summary of current and emerging pharmacologic therapies utilized in the treatment of diabetic retinopathy (DR). Current therapies, such as ranibizumab, bevacizumab, triamcinolone acetonide, and fluocinolone acetonide, inhibit angiogenesis and inflammation and may be used alone or in combination with laser treatment. Emerging therapies aim to reduce oxidative stress or inhibit other signal transduction pathways, including the protein kinase C cascade and aldose reductase pathway. Future therapies may target other molecules crucial to the pathogenesis of DR, including hepatocyte growth factors and matrix metalloproteinase 9. Finally, the emergence of novel mechanisms of medication delivery may also be on the horizon.

Citing Articles

An examination of the mechanisms driving the therapeutic effects of an AAV expressing a soluble variant of VEGF receptor-1.

Moon S, Kim H, Kim J, Kim J, Choi J, Won S PLoS One. 2024; 19(7):e0305466.

PMID: 38990973 PMC: 11239064. DOI: 10.1371/journal.pone.0305466.

Current Trends in Diagnosis and Treatment Approach of Diabetic Retinopathy during Pregnancy: A Narrative Review.

Rosu L, Prodan-Barbulescu C, Maghiari A, Bernad E, Bernad R, Iacob R Diagnostics (Basel). 2024; 14(4).

PMID: 38396408 PMC: 10887682. DOI: 10.3390/diagnostics14040369.

mTOR inhibition as a novel gene therapeutic strategy for diabetic retinopathy.

Lee S, Lee J, Choi J, Kim H, Kim J, Cha S PLoS One. 2022; 17(6):e0269951.

PMID: 35709240 PMC: 9202865. DOI: 10.1371/journal.pone.0269951.

Intravitreal diclofenac versus intravitreal bevacizumab in persistent diabetic macular edema: Anatomical and functional outcome.

Elbendary A, Elkannishy A Saudi J Ophthalmol. 2018; 32(4):303-309.

PMID: 30581301 PMC: 6300766. DOI: 10.1016/j.sjopt.2018.10.003.

Remodeling of Retinal Architecture in Diabetic Retinopathy: Disruption of Ocular Physiology and Visual Functions by Inflammatory Gene Products and Pyroptosis.

Homme R, Singh M, Majumder A, George A, Nair K, Sandhu H Front Physiol. 2018; 9:1268.

PMID: 30233418 PMC: 6134046. DOI: 10.3389/fphys.2018.01268.

References

Michaelides M, Kaines A, Hamilton R, Fraser-Bell S, Rajendram R, Quhill F . A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010; 117(6):1078-1086.e2. DOI: 10.1016/j.ophtha.2010.03.045. View

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

Schoenberger S, Kim S, Shah R, Sheng J, Cherney E . Reduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac, 0.45%, in patients with diabetic retinopathy. JAMA Ophthalmol. 2013; 132(1):32-7. DOI: 10.1001/jamaophthalmol.2013.6203. View

Ruigomez A, Garcia Rodriguez L . Presence of diabetes related complication at the time of NIDDM diagnosis: an important prognostic factor. Eur J Epidemiol. 1998; 14(5):439-45. DOI: 10.1023/a:1007484920656. View

Nakano Goto S, Yamamoto T, Kirii E, Abe S, Yamashita H . Treatment of diffuse diabetic macular oedema using steroid eye drops. Acta Ophthalmol. 2011; 90(7):628-32. DOI: 10.1111/j.1755-3768.2010.02066.x. View

Nishimura M, Nakano K, Ushiyama M, Nanbu A, Ohtsuka K, Takahashi H . Increased serum concentrations of human hepatocyte growth factor in proliferative diabetic retinopathy. J Clin Endocrinol Metab. 1998; 83(1):195-8. DOI: 10.1210/jcem.83.1.4499. View

Lachin J, Genuth S, Cleary P, Davis M, Nathan D . Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000; 342(6):381-9. PMC: 2630213. DOI: 10.1056/NEJM200002103420603. View

Gillies M, McAllister I, Zhu M, Wong W, Louis D, Arnold J . Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial. Ophthalmology. 2011; 118(5):866-72. DOI: 10.1016/j.ophtha.2010.09.029. View

Feener E . Plasma kallikrein and diabetic macular edema. Curr Diab Rep. 2010; 10(4):270-5. DOI: 10.1007/s11892-010-0127-1. View

10.

. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985; 103(12):1796-806. View

11.

Danis R, Bingaman D, Jirousek M, Yang Y . Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthalmol Vis Sci. 1998; 39(1):171-9. View

12.

. Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report no. 3. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin. 1987; 27(4):254-64. DOI: 10.1097/00004397-198702740-00005. View

13.

Zhang X, Lassila M, Cooper M, Cao Z . Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptors. Hypertension. 2004; 43(2):276-81. DOI: 10.1161/01.HYP.0000113628.94574.0f. View

14.

Rangasamy S, Srinivasan R, Maestas J, McGuire P, Das A . A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2011; 52(6):3784-91. PMC: 3109054. DOI: 10.1167/iovs.10-6386. View

15.

Beck R, Edwards A, Aiello L, Bressler N, Ferris F, Glassman A . Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009; 127(3):245-51. PMC: 2754047. DOI: 10.1001/archophthalmol.2008.610. View

16.

Xu H, Zhang L, Gu L, Lu L, Gao G, Li W . Subretinal delivery of AAV2-mediated human erythropoietin gene is protective and safe in experimental diabetic retinopathy. Invest Ophthalmol Vis Sci. 2014; 55(3):1519-30. DOI: 10.1167/iovs.13-13155. View

17.

Kaji Y, Usui T, Ishida S, Yamashiro K, Moore T, Moore J . Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci. 2007; 48(2):858-65. DOI: 10.1167/iovs.06-0495. View

18.

Sfikakis P, Markomichelakis N, Theodossiadis G, Grigoropoulos V, Katsilambros N, Theodossiadis P . Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab. Diabetes Care. 2005; 28(2):445-7. DOI: 10.2337/diacare.28.2.445. View

19.

Hu B, Zhang Y, Zeng Q, Han Q, Zhang L, Liu M . Intravitreal injection of ranibizumab and CTGF shRNA improves retinal gene expression and microvessel ultrastructure in a rodent model of diabetes. Int J Mol Sci. 2014; 15(1):1606-24. PMC: 3907889. DOI: 10.3390/ijms15011606. View

20.

Kuppermann B, Thomas E, Smet M, Grillone L . Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol. 2005; 140(4):585-97. DOI: 10.1016/j.ajo.2005.06.022. View